The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Most doses of Eli Lilly's highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year due to increased demand, according to an update on the Food and Drug Administration's drug shortage database.The new update suggests that the insatiable demand for a buzzy class of weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production of those treatments.
By that point in the year, the company expects its production of sellable doses of incretin drugs to be at least 1.5 times higher than it was in the second half of 2023. Eli Lilly has also said that a new plant in Concord, North Carolina, will start production of incretin drugs as early as the end of the year, with products available to ship in 2025. The company also will build a handful of other facilities over the next few years, including a site in Germany and two new plants in its home state of Indiana.
Novo Nordisk has announced similar efforts. Some doses of Novo Nordisk's weight loss drug Wegovy and diabetes counterpart Ozempic are also in short supply, according to the FDA's website.
Biotechnology Biotech And Pharmaceuticals Pharmaceuticals Health Care Industry Eli Lilly And Co Novo Nordisk A/S Novo Nordisk A/S Breaking News Business News
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Lire la suite »
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trialsThe pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Lire la suite »
Eli Lilly Warns That 2 Insulin Products Will Be in Short SupplyDrugmaker Eli Lilly & Co is announcing a temporary shortage of two of its insulin products.
Lire la suite »
Eli Lilly warns 2 of its insulin products may be out of stockThe shortage applies to the company's 10 mL vials of Humalog and Insulin Lispro Injection medications.
Lire la suite »
Stocks making the biggest premarket moves: Eli Lilly, Travelers, United Airlines, Alcoa and moreThese are the stocks posting the largest moves in the premarket.
Lire la suite »